Sign In
Buy TTI
$9.45
+0.0300 (+0.318%)
At Close: Jul 10, 2026
Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome
06:00am, Monday, 13'th Jul 2026
San Diego, California--(Newsfile Corp. - July 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) an
Tetra Technologies (TTI) Soars 6.6%: Is Further Upside Left in the Stock?
03:10pm, Monday, 29'th Jun 2026
Tetra Technologies (TTI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
TETRA TECHNOLOGIES INTRODUCES TETRA NEPTUNE Z-LITE DEEPWATER COMPLETIONS FLUID
07:00am, Monday, 29'th Jun 2026
Using Neptune Chemistry to Achieve Required Density With Lower Zinc Content; Awarded Three-Well 20k psi Deepwater Project in the Gulf of America With Estimated Start in 2026 SPRING, Texas, June 29, 2
TETRA Technologies, Inc. (TTI) Presents at J.P. Morgan Natural Resources Conference 2026 Transcript
01:32pm, Wednesday, 24'th Jun 2026
TETRA Technologies, Inc. (TTI) Presents at J.P. Morgan Natural Resources Conference 2026 Transcript
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
08:00am, Wednesday, 17'th Jun 2026
San Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing
Can Viavi's New TETRA Testing Upgrade Strengthen Its Growth Story?
10:26am, Tuesday, 16'th Jun 2026
VIAV's new TETRA testing upgrade for the CX300 aims to speed deployments, cut costs, and reinforce its position in mission-critical radio testing.
VIAVI Launches TETRA MS Base Station Simulator Option for CX300 to Simplify and Speed Mission-Critical Radio Testing
06:30am, Monday, 15'th Jun 2026
Allows full testing of TETRA MS radios, including transmitter parametric measurements, call processing and BER/MER loopback without the need to place radios in T1 test mode CHANDLER, Ariz., June 15, 2
Is TETRA Technologies a Buy After An Insider Bought 22,000 Shares?
11:51am, Saturday, 13'th Jun 2026
Hallead acquired 22,000 shares on June 9, 2026, at a weighted average price of $9.86 per share, representing a transaction value of ~$217,000. This purchase increased his direct ownership by 14.79%, b
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
06:00am, Wednesday, 03'rd Jun 2026
San Diego, California--(Newsfile Corp. - June 3, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generatio
TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock
12:00am, Wednesday, 03'rd Jun 2026
TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire SPRING, Texas, June 2,
TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock
11:36pm, Tuesday, 02'nd Jun 2026
SPRING, Texas, June 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) today announced the pricing of an underwritten public offering of 10,810,811 shares of its c
TETRA TECHNOLOGIES, INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK
04:05pm, Tuesday, 02'nd Jun 2026
SPRING, Texas, June 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) today announced the commencement of an underwritten public offering of $100 million of share
Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
02:49pm, Monday, 01'st Jun 2026
San Diego, California--(Newsfile Corp. - June 1, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing
